in patients receiving multi-drug therapy are of wide spread. Such interactions are one of the important cause of adverse drug reactions (ADRs) and may lead to increased risk of mortality and morbidity. Hence, health cost will increase. This study estimates to find out the potential DDIs among the hospitalized patients. The final results of the study concluded with a major preponderance towards ATORVASTATIN
No takes yet. Share an insight, caveat, or question.
Bhavana Chowdary M (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: